Selected Peer-reviewed Publications
Tissue-specific abundance of interferon-gamma drives regulatory T cells to restrain DC1-mediated priming of cytotoxic T cells against lung cancer. Zagorulya M, Yim L, Morgan DM, Edwards A, Torres-Mejia E, Momin N, McCreery CV, Zamora IL, Horton BL, Fox JG, Wittrup KD, Love JC, Spranger S. Immunity. 2023 Jan 26:S1074-7613(23)00020-1. doi: 10.1016/j.immuni.2023.01.010.
Summaries: Cancer Discovery, ACIR, MIT News
Cover of 56/2 Immunity (Credit Maria Zagorulya)
Dendritic cell-mediated cross presentation of tumor-derived peptides is biased against plasma membrane proteins. Fessenden TB, Stopfer LE, Chatterjee F, Zulueta J, Mesfin J, Cordero Dumit T, Reijers I, Hoefsmit EP, Blank C, White F, Spranger S. J Immunother Cancer. 2022 Jul;10(7):e004159. doi: 10.1136/jitc-2021-004159.
Free access: https://jitc.bmj.com/content/10/7/e004159
Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity. Duong E, Fessenden TB, Lutz E, Dinter T, Yim L, Blatt S, Bhutkar A, Wittrup KD, Spranger S. Immunity. 2021 Nov 19. doi.org/10.1016/j.immuni.2021.10.020.
Summaries: ACIR, MIT, Cancer Research
Lack of CD8+ T cell effector differentiation during priming mediates checkpoint blockade resistance in non-small cell lung cancer. Horton BL, Morgan DM, Momin N, Zagorulya M, Torres-Mejia E, Bhandarkar V, Wittrup KD, Love JC, Spranger S. Sci Immunol. 2021 Oct 29;6(64):eabi8800. doi: 10.1126/sciimmunol.abi8800. Epub 2021 Oct 29. PMID: 34714687
Free access: https://www.science.org/stoken/author-tokens/ST-128/full
Increased demand for NAD+ relative to ATP drives aerobic glycolysis. Luengo A, Li Z, Gui DY, Sullivan LB, Zagorulya M, Do BT, Ferreira R, Naamati A, Ali A, Lewis CA, Thomas CJ, Spranger S, Matheson NJ, Vander Heiden MG. Mol Cell. 2020 Dec 22:S1097-2765(20)30904-7. doi: 10.1016/j.molcel.2020.12.012.
Direct and Indirect Regulators of Epithelial-Mesenchymal Transition (EMT)-mediated Immunosuppression in Breast Carcinomas. Dongre A, Rashidian M, Eaton EN, Reinhardt F, Thiru P, Zagorulya M, Nepal S, Banaz T, Martner A, Spranger S, Weinberg RA. Cancer Discov. 2020 Dec 16:CD-20-0603. doi: 10.1158/2159-8290.CD-20-0603.
Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy. Momin N, Mehta NK, Bennett NR, Ma L, Palmeri JR, Chinn MM, Lutz EA, Kang B, Irvine DJ, Spranger S, Wittrup KD. Sci Transl Med. 2019 Jun 26;11(498). pii: eaaw2614. doi: 10.1126/scitranslmed.aaw2614. PMID: 31243150
WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers. Luke JJ, Bao R, Sweis RF, Spranger S, Gajewski TF. Clin Cancer Res. 2019 May 15;25(10):3074-3083. doi: 10.1158/1078-0432.CCR-18-1942. Epub 2019 Jan 11. PMID: 30635339
Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T cell Therapy. Spranger S, Dai D, Horton B, Gajewski TF. Cancer Cell. 2017 May 8;31(5):711-723.e4. doi: 10.1016/j.ccell.2017.04.003.
Density of immunogenic antigens does not explain the presence or absence of the T cell-inflamed tumor microenvironment in melanoma. Spranger S*, Luke JJ*, Bao R, Zha Y, Hernandez K, Li Y, Gajewski AP, Andrade J, Gajewski TF. Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7759-E7768. Epub 2016 Nov 11.
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Spranger S, Bao R, and Gajewski TF, Nature. 2015 Jul 9;523(7559):231-5. doi: 10.1038/nature14404. Epub 2015 May 11.
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment. Spranger S, Koblish H, Horton B, Scherle P, Newton R, Gajewski TF, J Immunother Cancer. 2014 Feb 18;2:3. doi: 10.1186/2051-1426-2-3. eCollection 2014.
Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF, Sci Transl Med. 2013 Aug 28;5(200):200ra116. doi: 10.1126/scitranslmed.3006504.
Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL. Nagel D, Spranger S, Vincendeau M, Grau M, Raffegerst S, Kloo B, Hlahla D, Neuenschwander M, Peter von Kries J, Hadian K, Dörken B, Lenz P, Lenz G, Schendel DJ, Krappmann D, Cancer Cell. 2012 Dec 11;22(6):825-37. doi: 10.1016/j.ccr.2012.11.002.
T cell receptor-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo. Spranger S, Jeremias I, Wilde S, Leisegang M, Stärk L, Mosetter B, Uckert W, Heemskerk MH, Schendel DJ and Frankenberger B, Blood. 2012 Apr 12;119(15):3440-9. doi: 10.1182/blood-2011-06-357939. Epub 2012 Feb 27.
*authors contributed equally
Selected Reviews, Commentaries and Book chapters
Impact of anatomic site on antigen-presenting cells in cancer. Zagorulya M*, Duong E*, Spranger S. J Immunother Cancer. 2020 Oct;8(2):e001204. doi: 10.1136/jitc-2020-001204. PMID: 33020244 Review.
CD36 - the Achilles' heel of Treg cells. Horton BL, Spranger S. Nat Immunol. 2020 Mar;21(3):251-253. doi: 10.1038/s41590-020-0601-0. PMID: 32066948
Modulation of the immune microenvironment by tumor-intrinsic oncogenic signaling. Nguyen KB, Spranger S. J Cell Biol. 2020 Jan 6;219(1). pii: e201908224. doi: 10.1083/jcb.201908224. PMID: 31816057
Tissue Site and the Cancer Immunity Cycle. Horton BL, Fessenden TB, Spranger S. Trends Cancer. 2019 Oct;5(10):593-603. doi: 10.1016/j.trecan.2019.07.006. Epub 2019 Aug 13. Review. PMID: 31706507
WNT Signaling in Cancer Immunosurveillance. Galluzzi L, Spranger S, Fuchs E, López-Soto A. Trends Cell Biol. 2019 Jan;29(1):44-65. doi: 10.1016/j.tcb.2018.08.005. Epub 2018 Sep 13. Review. PMID: 30220580
A Tumor Cell-Intrinsic Yin-Yang Determining Immune Evasion. Horton B, Spranger S. Immunity. 2018 Jul 17;49(1):11-13. doi: 10.1016/j.immuni.2018.07.001. PMID: 30021140
A team effort: natural killer cells on the first leg of the tumor immunity relay race. Fessenden TB, Duong E, Spranger S. J Immunother Cancer. 2018 Jul 9;6(1):67. doi: 10.1186/s40425-018-0380-4. PMID: 29986768
Impact of oncogenic pathways on evasion of antitumour immune responses. Spranger S, Gajewski TF. Nat Rev Cancer. 2018 Mar;18(3):139-147. doi: 10.1038/nrc.2017.117. Epub 2018 Jan 12. Review. PMID: 29326431